Anthony Fauci, AP Images

Mod­er­na bol­sters glob­al hopes in Covid-19 vac­cines, but big ob­sta­cles re­main

Where does the world go from here?

Eleven months af­ter word first broke out, two com­pa­nies now say they have de­vel­oped an ef­fec­tive Covid-19 vac­cine, a key tri­umph in the fight against the worst pan­dem­ic in a cen­tu­ry and the first ma­jor round of ev­i­dence for a pre­vi­ous­ly untest­ed ge­net­ic tech­nol­o­gy whose rapid re­sponse po­ten­tial long cap­tured the imag­i­na­tions of re­searchers in the US and Eu­rope.

Ex­perts cau­tioned for months that mR­NA was un­proven and the first vac­cines may on­ly be 60% or 70% ef­fec­tive, if they worked at all. Now both fron­trun­ners say they pre­vent dis­ease more than 90% of the time.

“All the box­es have now been checked,” NI­AID chief Tony Fau­ci told re­porters Mon­day morn­ing. “The plat­form clear­ly works, it worked here with Mod­er­na, it worked with Pfiz­er.”

Al­though both rounds of re­sults came by press re­lease, Mod­er­na’s an­nounce­ment clar­i­fied key ques­tions. They gave the first snap­shots for safe­ty da­ta and the first de­mo­graph­ic break­down of who came down with Covid-19 in the tri­al.

They al­so showed that it like­ly helped pre­vent hos­pi­tal­iza­tion and death, with 11 cas­es of se­vere dis­ease oc­cur­ring in the place­bo group and ze­ro oc­cur­ring in the vac­cine group, an­swer­ing a key ques­tion FDA ad­vi­sors raised dur­ing a re­cent com­mit­tee hear­ing.

Paul Of­fit

“Ar­guably it’s 100% ef­fec­tive at pre­vent­ing se­vere dis­ease based on those da­ta,” Paul Of­fit, di­rec­tor of the Vac­cine Ed­u­ca­tion Cen­ter and a mem­ber of the FDA vac­cine ad­vi­so­ry com­mit­tee, told End­points News. “But it’s not shock­ing. It’s ac­tu­al­ly hard­er to pre­vent mild dis­ease.”

And yet the US and the world still face the same ques­tion that has al­ways loomed at the end of the first ma­jor tri­als: how to scale up a vac­cine once it’s au­tho­rized, and how to get vac­cine-skep­tic cor­ners of the coun­try to take it once it’s avail­able.

The six com­pa­nies in­volved in Op­er­a­tion Warp Speed have all talked about mak­ing a huge num­ber of dos­es for next year, and the gov­ern­ment has in­vest­ed in scal­ing up their tech­nol­o­gy. Still, bi­o­log­ics are tricky to pro­duce, and Mod­er­na and Pfiz­er say they will on­ly be able to make enough to vac­ci­nate 20 mil­lion Amer­i­cans com­bined this year. At one point, US of­fi­cials had talked about hav­ing 300 mil­lion dos­es avail­able by Jan­u­ary.

Jesse Good­man

“I was struck by the rel­a­tive­ly low num­ber of dos­es,” for­mer FDA chief sci­en­tist Jesse Good­man told End­points. “Scale-up of these tech­nolo­gies is some­thing we’re all still learn­ing about and we have to keep our fin­gers crossed that that all goes well.”

There’s a chance that the US gov­ern­ment could look to ex­er­cise the De­fense Pro­duc­tion Act to ramp up man­u­fac­tur­ing, Warp Speed vac­cine lead Matthew Hep­burn told re­porters Mon­day, al­though he cau­tioned that they were “look­ing at all the tools avail­able.”

Still, the da­ta to­day show­ing Mod­er­na can keep their vac­cine at re­frig­er­a­tor tem­per­a­tures were cru­cial, gov­ern­ment of­fi­cials and out­side ex­perts said, help­ing al­le­vi­ate con­cerns about how well rur­al ar­eas will be able to han­dle the -70 de­gree cold chain Pfiz­er’s vac­cine re­quired.

“This is re­al­ly good news,” Nor­bert Par­di, who stud­ies mR­NA vac­cines at the Uni­ver­si­ty of Penn­syl­va­nia, told End­points.

Nor­bert Par­di

Mod­er­na CEO Stéphane Ban­cel said in an in­ter­view with End­points Sun­day that the biggest lim­it­ing step for the com­pa­ny’s man­u­fac­tur­ing was raw ma­te­r­i­al, as they have al­ready built the ca­pac­i­ty and hired the staff to ramp up to max­i­mum pro­duc­tion. They should be able to make be­tween 500 mil­lion and 1 bil­lion vac­cines next year, he said.

No plans have yet been fi­nal­ized for rolling out the vac­cine, with US of­fi­cials putting much of the bur­den on cash-strapped states. De­spite those ob­sta­cles, Fau­ci re­it­er­at­ed Mon­day that he ex­pects the vac­cine will be able to be rolled out to the gen­er­al pop­u­la­tion by April.

By that time, oth­er vac­cines will like­ly al­so have crossed the fin­ish line, in­clud­ing a one-shot vi­ral vec­tor in­oc­u­la­tion from J&J, a two-shot jab from As­traZeneca and pro­tein-based vac­cines from Sanofi and No­vavax. They will all still have to prove them­selves in late-stage tri­als, but the Mod­er­na and Pfiz­er news has bol­stered con­fi­dence, par­tic­u­lar­ly in the vi­ral vec­tor vac­cines.

The vec­tors op­er­ate on a sim­i­lar ge­net­ic prin­ci­ple to the mR­NA vac­cines, de­liv­er­ing in­struc­tions for cells to pro­duce the coro­n­avirus spike pro­tein.

“You can ar­gue this val­i­dates the gen­er­al ap­proach,” Of­fit said. “They’re just dif­fer­ent ways of get­ting the gene in­side cells.”

Still, de­spite the ear­ly signs of suc­cess, mR­NA still has its skep­tics. Maria Bot­tazzi, a vac­ci­nol­o­gist at Bay­lor Uni­ver­si­ty who is de­vel­op­ing a pro­tein-based Covid-19 vac­cine, said that the speed of the plat­form made sense for tack­ling more con­trolled out­breaks. But she ar­gued that giv­en the size of the cur­rent pan­dem­ic, more mon­ey should have gone to­ward ac­cel­er­at­ing pro­tein-based vac­cines.

Maria Bot­tazzi

These ap­proach­es are more scal­able and ear­ly stud­ies in­duced more neu­tral­iz­ing an­ti­bod­ies, she said, po­ten­tial­ly con­fer­ring longer-term pro­tec­tion. She al­so ques­tioned whether the side ef­fect pro­file — fa­tigue in 9.7% of par­tic­i­pants and mus­cle ache in 8.9% — could make some hes­i­tant to take the vac­cine.

“The ad­verse events and the range of the scor­ing — it’s not fab­u­lous,” she said. “These have to be de­ployed in a large num­ber of peo­ple, in high ed­u­ca­tion and low ed­u­ca­tion, and we have to make sure some peo­ple use it and we al­ready know con­fi­dence is not very high.”

Par­di said the safe­ty da­ta was “ac­cept­able,” but Of­fit said he need­ed to see the full analy­sis. He not­ed that the Phase I tri­al in­di­cat­ed high­er rates of side ef­fects, in­clud­ing fever.  That would make it sim­i­lar to the shin­gles vac­cine from Glax­o­SmithK­line, Shin­grix.

“Of­ten peo­ple will say to peo­ple that get Shin­grix, get it on Fri­day, so you don’t miss a day of work,” Of­fit said. “If there’s fever and enough side ef­fects as­so­ci­at­ed with fever that would cause one to miss a day of work, you have to make sure that if you’re vac­ci­nat­ing your ER staff, you don’t vac­ci­nate them all the same day.”

Sev­er­al ques­tions around im­mu­ni­ty and pro­tec­tion still re­main, in­clud­ing whether or not the Pfiz­er or Mod­er­na vac­cine can pre­vent peo­ple from get­ting in­fect­ed or re­duce the amount of virus they shed. That would give of­fi­cials key in­for­ma­tion on whether and when mea­sures like so­cial dis­tanc­ing can be eased, al­though ex­perts cau­tioned that the vac­cines are un­like­ly to ful­ly stop in­fec­tion and the stud­ies are not well-de­signed to prove if one did.

The big­ger ques­tion will be over dura­bil­i­ty, a ques­tion that on­ly time can an­swer. When the FDA re­views the vac­cines, most par­tic­i­pants will on­ly be two months past in­oc­u­la­tion.

“I’m op­ti­mistic,” Par­di said. “But I al­ways need to men­tion and I al­ways need to em­pha­size long-term fol­lowup will be crit­i­cal and long-term fol­lowup will de­ter­mine the ac­tu­al ef­fi­ca­cy.”

For a look at all End­points News coro­n­avirus sto­ries, check out our spe­cial news chan­nel.

Biogen CEO Michel Vounatsos (via Getty Images)

With ad­u­canum­ab caught on a cliff, Bio­gen’s Michel Vounatsos bets bil­lions on an­oth­er high-risk neu­ro play

With its FDA pitch on the Alzheimer’s drug aducanumab hanging perilously close to disaster, Biogen is rolling the dice on a $3.1 billion deal that brings in commercial rights to one of the other spotlight neuro drugs in late-stage development — after it already failed its first Phase III.

The big biotech has turned to Sage Therapeutics for its latest deal, close to a year after the crushing failure of Sage-217, now dubbed zuranolone, in the MOUNTAIN study.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,200+ biopharma pros reading Endpoints daily — and it's free.

Pascal Soriot (AP Images)

As­traZeneca, Ox­ford on the de­fen­sive as skep­tics dis­miss 70% av­er­age ef­fi­ca­cy for Covid-19 vac­cine

On the third straight Monday that the world wakes up to positive vaccine news, AstraZeneca and Oxford are declaring a new Phase III milestone in the fight against the pandemic. Not everyone is convinced they will play a big part, though.

With an average efficacy of 70%, the headline number struck analysts as less impressive than the 95% and 94.5% protection that Pfizer/BioNTech and Moderna have boasted in the past two weeks, respectively. But the British partners say they have several other bright spots going for their candidate. One of the two dosing regimens tested in Phase III showed a better profile, bringing efficacy up to 90%; the adenovirus vector-based vaccine requires minimal refrigeration, which may mean easier distribution; and AstraZeneca has pledged to sell it at a fraction of the price that the other two vaccine developers are charging.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,200+ biopharma pros reading Endpoints daily — and it's free.

Jason Kelly, Ginkgo Bioworks CEO (Kyle Grillot/Bloomberg via Getty Images)

Af­ter Ko­dak de­ba­cle, US lends $1.1B to a syn­thet­ic bi­ol­o­gy com­pa­ny and their big Covid-19, mR­NA plans

In mid-August, as Kodak’s $765 million government-backed push into drug manufacturing slowly fell apart in national headlines, Ginkgo Bioworks CEO Jason Kelly got a message from his company’s government liaison: HHS wanted to know if they, too, might want a loan.

The government’s decision to lend Kodak three quarters of a billion dollars raised eyebrows because Kodak had never made drugs before. But Ginkgo, while not a manufacturing company, had spent the last decade refining new ways to produce materials inside cells and building automated facilities across Boston.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,200+ biopharma pros reading Endpoints daily — and it's free.

In fi­nal days at Mer­ck, Roger Perl­mut­ter bets big on a lit­tle-known Covid-19 treat­ment

Roger Perlmutter is spending his last days at Merck, well, spending.

Two weeks after snapping up the antibody-drug conjugate biotech VelosBio for $2.75 billion, Merck announced today that it had purchased OncoImmune and its experimental Covid-19 drug for $425 million. The drug, known as CD24Fc, appeared to reduce the risk of respiratory failure or death in severe Covid-19 patients by 50% in a 203-person Phase III trial, OncoImmune said in September.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,200+ biopharma pros reading Endpoints daily — and it's free.

Leonard Schleifer, Regeneron CEO (Andrew Harnik/AP)

Trail­ing Eli Lil­ly by 12 days, Re­gen­eron gets the FDA OK for their Covid-19 an­ti­body cock­tail

A month and a half after becoming the experimental treatment of choice for a newly diagnosed president, Regeneron’s antibody cocktail has received emergency use authorization from the FDA. It will be used to treat non-hospitalized Covid-19 patients who are at high-risk of progressing.

Although the Rgeneron drug is not the first antibody treatment authorized by the FDA, the news comes as a significant milestone for a company and a treatment scientists have watched closely since the outbreak began.

FDA hands Liq­uidia and Re­vance a CRL and de­fer­ral, re­spec­tive­ly, as Covid-19 cre­ates in­spec­tion chal­lenge

Two biotechs said they got turned away by the FDA on Wednesday, in part due to pandemic-related travel restrictions.

North Carolina-based Liquidia Technologies was handed a CRL for its lead pulmonary arterial hypertension drug, citing the need for more CMC data and on-site pre-approval inspections, which the FDA hasn’t been able to conduct due to travel restrictions. The agency also deferred its decision on Revance Therapeutics’ BLA for its frown line treatment, because it needs to inspect the company’s northern California manufacturing facility. The action, Revance emphasized, was not a CRL.

Covid-19 roundup: Eu­rope pur­chas­es 80M dos­es of Mod­er­na's vac­cine; CO­V­AXX se­cures $2.8B in emerg­ing mar­ket pre-or­ders

With the announcement of its vaccine efficacy data last week, Moderna is starting to line up customers for its Covid-19 mRNA jabs.

The Massachusetts-based biotech announced Wednesday it has agreed to sell an initial round of 80 million doses to the European Commission, with the option to double the amount to 160 million. Once the member states rubber stamp the approval, the deal will be finalized.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,200+ biopharma pros reading Endpoints daily — and it's free.

The ad­u­canum­ab co­nun­drum: The PhI­II failed a clear reg­u­la­to­ry stan­dard, but no one is cer­tain what that means any­more at the FDA

Eighteen days ago, virtually all of the outside experts on an FDA adcomm got together to mug the agency’s Billy Dunn and the Biogen team when they presented their upbeat assessment on aducanumab. But here we are, more than 2 weeks later, and the ongoing debate over that Alzheimer’s drug’s fate continues unabated.

Instead of simply ruling out any chance of an approval, the logical conclusion based on what we heard during that session, a series of questionable approvals that preceded the controversy over the agency’s recent EUA decisions has come back to haunt the FDA, where the power of precedent is leaving an opening some experts believe can still be exploited by the big biotech.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

A poll sug­gests vac­cine da­ta boost­ed Pfiz­er's pub­lic im­age, but oth­er da­ta point to long road ahead

For much of the pharmaceutical industry, the pandemic presented an opportunity: to prove their value to the world and turn public opinion around on a business much of the country had come to disdain.

That theory — that helping pull the country from a pandemic could neutralize years of anger over high drug prices — was put to its biggest test this month, as three different drugmakers announced data from their Covid-19 vaccines, offering the first major evidence that industry-built inoculations could turn the tide of the outbreak in the US.